{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:24:11Z","timestamp":1773282251313,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["canadianjournalofophthalmology.ca","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Ophthalmology"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.jcjo.2012.12.003","type":"journal-article","created":{"date-parts":[[2013,10,4]],"date-time":"2013-10-04T15:39:16Z","timestamp":1380901156000},"page":"115-120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Effects of subconjunctivally injected bevacizumab, etanercept, and the combination of both drugs on experimental corneal neovascularization"],"prefix":"10.1016","volume":"48","author":[{"given":"Ozdemir","family":"Ozdemir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ozgul","family":"Altintas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Levent","family":"Altintas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Demir Kursat","family":"Yildiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ender","family":"Sener","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuf","family":"Caglar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjo.2012.12.003_bib1","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0039-6257(96)00007-0","article-title":"Chemical injuries of the eye: current concepts in pathophysiology and therapy","volume":"41","author":"Wagoner","year":"1997","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.jcjo.2012.12.003_bib2","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0161-6420(00)00289-X","article-title":"Management of alkali burns: an 11-year retrospective review","volume":"107","author":"Brodovsky","year":"2000","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2012.12.003_bib3","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/00003226-199309000-00003","article-title":"Epithelial basement membrane in alkali-burned corneas in rats. Immunohistochemical study","volume":"12","author":"Saika","year":"1993","journal-title":"Cornea"},{"key":"10.1016\/j.jcjo.2012.12.003_bib4","first-page":"3320","article-title":"Expression of collagen I, smooth muscle a-actin, and vimentin during the healing of alkali-burned and lacerated corneas","volume":"34","author":"Ishizaki","year":"1993","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jcjo.2012.12.003_bib5","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/00055735-200108000-00002","article-title":"Corneal neovascularization","volume":"12","author":"Chang","year":"2001","journal-title":"Curr Opin Ophthalmol."},{"key":"10.1016\/j.jcjo.2012.12.003_bib6","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/00003226-198706040-00004","article-title":"Corneal neovascularization: pathogenesis and inhibition","volume":"6","author":"Epstein","year":"1987","journal-title":"Cornea"},{"key":"10.1016\/j.jcjo.2012.12.003_bib7","first-page":"2514","article-title":"Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas","volume":"41","author":"Philipp","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jcjo.2012.12.003_bib8","first-page":"961","article-title":"Vascular endothelial growth factor (rhVEGF165) stimulates direct angiogenesis in the rabbit cornea","volume":"8","author":"Phillips","year":"1994","journal-title":"In Vivo"},{"key":"10.1016\/j.jcjo.2012.12.003_bib9","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/00003226-200007000-00025","article-title":"Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor alpha, and transforming growth factor beta1 in human corneas with neovascularization","volume":"19","author":"Cursiefen","year":"2000","journal-title":"Cornea"},{"key":"10.1016\/j.jcjo.2012.12.003_bib10","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.preteyeres.2008.11.005","article-title":"Therapeutic monoclonal antibodies in ophthalmology","volume":"28","author":"Rodrigues","year":"2009","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.jcjo.2012.12.003_bib11","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/ICO.0b013e31812f6d14","article-title":"Yin and yang in cytokine regulation of corneal wound healing roles of TNF-\u03b1","volume":"26","author":"Saika","year":"2007","journal-title":"Cornea"},{"key":"10.1016\/j.jcjo.2012.12.003_bib12","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1046\/j.1365-2249.2000.01339.x","article-title":"Local bioactive tumour necrosis factor (TNF) in corneal allotransplantation","volume":"122","author":"Rayner","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jcjo.2012.12.003_bib13","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1177\/0091270004273321","article-title":"Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein","volume":"45","author":"Zhou","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jcjo.2012.12.003_bib14","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/09273940600659393","article-title":"Etanercept (Enbrel)-associated inflammatory eye disease: case report and review of the literature","volume":"14","author":"Taban","year":"2006","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.jcjo.2012.12.003_bib15","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.exer.2004.06.001","article-title":"Etanercept treatment in the endotoxin-induced uveitis of rats","volume":"79","author":"Avunduk","year":"2004","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.jcjo.2012.12.003_bib16","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1002\/1529-0131(200106)44:6<1411::AID-ART235>3.0.CO;2-O","article-title":"Etanercept therapy in children with treatment-resistant uveitis","volume":"44","author":"Reiff","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jcjo.2012.12.003_bib17","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/1529-0131(200106)45:3<252::AID-ART257>3.0.CO;2-5","article-title":"Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease","volume":"45","author":"Smith","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jcjo.2012.12.003_bib18","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3109\/02713688508999984","article-title":"Drug effects on the neovascularization response to silver nitrate cauterization of the rat cornea","volume":"4","author":"Mahoney","year":"1985","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.jcjo.2012.12.003_bib19","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/emm.2006.21","article-title":"Inhibition of corneal neovascularization by rapamycin","volume":"38","author":"Kwon","year":"2006","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.jcjo.2012.12.003_bib20","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/archopht.1992.01080150103037","article-title":"Suppression of corneal neovascularization with cyclosporine","volume":"110","author":"Lipman","year":"1992","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jcjo.2012.12.003_bib21","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1006\/exer.1999.0790","article-title":"Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-associated corneal neovascularization","volume":"70","author":"Kvanta","year":"2000","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.jcjo.2012.12.003_bib22","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.3109\/02713683.2011.601840","article-title":"The impact of subconjunctivally injected EGF and VEGF inhibitors on experimental corneal neovascularization in rat model","volume":"36","author":"Sener","year":"2011","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.jcjo.2012.12.003_bib23","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00417-007-0587-4","article-title":"Subconjunctival bevacizumab for corneal neovascularization","volume":"245","author":"Erdurmus","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jcjo.2012.12.003_bib24","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ajo.2007.11.003","article-title":"Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model","volume":"145","author":"Papathanassiou","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2012.12.003_bib25","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/ICO.0b013e318160d019","article-title":"Effect of subconjunctival bevacizumab (avastin) on experimental corneal neovascularization in Guinea pigs","volume":"27","author":"Hurmeric","year":"2008","journal-title":"Cornea"},{"key":"10.1016\/j.jcjo.2012.12.003_bib26","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/ICO.0b013e318159019f","article-title":"Subconjunctival bevacizumab injection for corneal neovascularization","volume":"27","author":"Bahar","year":"2008","journal-title":"Cornea"},{"key":"10.1016\/j.jcjo.2012.12.003_bib27","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/ICO.0b013e31815cf67d","article-title":"Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin)","volume":"27","author":"Kim","year":"2008","journal-title":"Cornea"},{"key":"10.1016\/j.jcjo.2012.12.003_bib28","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1590\/S0001-37652007000300004","article-title":"The effects of the subconjunctival injection of bevacizumab on angiogenesis in the rat cornea","volume":"79","author":"Barros","year":"2007","journal-title":"An Acad Bras Cienc"},{"key":"10.1016\/j.jcjo.2012.12.003_bib29","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1442-9071.2007.01572.x","article-title":"Bevacizumab inhibits corneal neovascularization in an alkali burn-induced model of corneal angiogenesis","volume":"35","author":"Hosseini","year":"2007","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.jcjo.2012.12.003_bib30","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1755-3768.2008.01399.x","article-title":"Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization","volume":"87","author":"You","year":"2009","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.jcjo.2012.12.003_bib31","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.exer.2006.07.007","article-title":"Inhibition of TNF-a reduces laser-induced choroidal neovascularization","volume":"83","author":"Shi","year":"2006","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.jcjo.2012.12.003_bib32","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ajo.2004.09.058","article-title":"Regression of neovascular age-related macular degeneration following infliximab therapy","volume":"139","author":"Markomichelakis","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2012.12.003_bib33","first-page":"1891","article-title":"The potential angiogenic role of macrophages in the formation of choroidal neovascular membranes","volume":"40","author":"Oh","year":"1999","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jcjo.2012.12.003_bib34","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.ajo.2008.12.004","article-title":"Intravitreal administration of the anti-tumor necrosis factor agent infliximab for neovascular age-related macular degeneration","volume":"147","author":"Panagiotis","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2012.12.003_bib35","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/archopht.125.9.1221","article-title":"Intravitreal infliximab and choroidal neovascularization in an animal model","volume":"125","author":"Olson","year":"2007","journal-title":"Arch Ophthalmol"},{"issue":"Suppl 7","key":"10.1016\/j.jcjo.2012.12.003_bib36","doi-asserted-by":"crossref","first-page":"S126","DOI":"10.5301\/ejo.5000050","article-title":"Triple therapy for corneal neovascularization: a case report","volume":"22","author":"Veritti","year":"2012","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.jcjo.2012.12.003_bib37","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/ICO.0b013e3181b1c82f","article-title":"The effect of subconjunctival combined treatment of bevacizumab and triamcinolone acetonide on corneal neovascularization in rabbits","volume":"29","author":"Kang","year":"2010","journal-title":"Cornea"},{"key":"10.1016\/j.jcjo.2012.12.003_bib38","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1442-9071.2010.02252.x","article-title":"Inhibition of corneal neovascularization after alkali burn: comparison of different doses of bevacizumab in monotherapy or associated with dexamethasone","volume":"38","author":"Hoffart","year":"2010","journal-title":"Clin Exp Ophthalmol"}],"container-title":["Canadian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418212005649?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418212005649?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T20:02:21Z","timestamp":1757793741000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008418212005649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S0008418212005649"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjo.2012.12.003","relation":{},"ISSN":["0008-4182"],"issn-type":[{"value":"0008-4182","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of subconjunctivally injected bevacizumab, etanercept, and the combination of both drugs on experimental corneal neovascularization","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjo.2012.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}